Drugs / Recombinant human Interleukin-15 (rhIL-15)
Recombinant human Interleukin-15 (rhIL-15)
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04185220 | Feb → Nov 2020 | Sezary syndrome, adult T-cell leukemia/lymphoma, mycosis fungoides | National Cancer Institute (NCI) | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Recombinant human Interleukin-15 (rhIL-15) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04185220 ↗ |
| Modality | Protein / enzyme biologic | “recombinant human Interleukin-15 (rhIL-15), a stimulatory cytokine” NCT04185220 ↗ |
| Route | Intravenous | “Interleukin-15 (IL-15) by continuous intravenous (CIV) infusion” NCT04185220 ↗ |